Jane Alder
University of Central Lancashire
15 Papers
15 Citations
Jane Alder is an academic researcher from University of Central Lancashire. The author has contributed to research in topics: Glioma & Biology. The author has an hindex of 6, co-authored 12 publications.
Chat about Author
Papers
A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells
Carla Lucia Esposito,Silvia Nuzzo,Swati A. Kumar,Anna Rienzo,Clare Louise Lawrence,Roberto Pallini,Lisa Shaw,Jane Alder,Lucia Ricci-Vitiani,Silvia Catuogno,Vittorio de Franciscis +10 more
TL;DR: A combinational approach to target the GSC population with multiple miRNA-based therapeutics using two aptamers that bind to, and inhibit, the receptor tyrosine kinases, Axl and PDGFRβ and it is shown that the aptamer conjugates are transported through an in vitro blood-brain barrier model.
77
Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening.
Melissa A. Baxter,Cliff Rowe,Jane Alder,Sean Harrison,Karen Piper Hanley,B. Kevin Park,Neil R. Kitteringham,Christopher E. Goldring,Neil A. Hanley +8 more
TL;DR: The potential use of pluripotent stem cells in the generation of hepatic cell lineages is addressed and an effort is made to identify where some of the major barriers remain in translating what is currently hypothesis-driven laboratory research into meaningful platform technologies for the pharmaceutical industry.
75
Circulating MicroRNA Biomarkers for Glioma and Predicting Response to Therapy
TL;DR: This review will discuss current research into the role of miRNA in glioma and altered miRNA expression in biofluids as candidate biomarkers with a particular focus on glioblastoma, the most malignant form ofglioma.
70
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature
Josie Hayes,Helene Thygesen,Charlotte Tumilson,Alastair Droop,Marjorie Boissinot,Thomas A. Hughes,David R. Westhead,Jane Alder,Lisa Shaw,Susan C Short,Sean E. Lawler +10 more
TL;DR: The potential of microRNA expression profiles to predict survival in glioblastoma is investigated and it is shown that high levels of micro RNA expression are associated with poor prognosis in this challenging disease.
67
Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB/BBTB models.
TL;DR: The present study rationally designed functional nanostructured lipid carriers (NLC) to tailor their BBB penetrating properties with high encapsulation of CNS negative chemotherapeutic drug docetaxel (DTX) to develop NLCs with effective permeation across in-vitro 3D BBB model without alteration in the integrity of the barrier.
36